For people living with chronic pulmonary aspergillosis (CPA), the idea of surgery can raise difficult questions. Some patients are told surgery might offer a chance of cure; others are advised very firmly against it. Both positions can be correct, depending on the individual situation.
This article explains when surgery may be considered, why it is often avoided, and what “success” or “cure” really means in CPA.
Why is surgery even considered in CPA
CPA usually develops in lungs that are already damaged (for example, by tuberculosis, chronic obstructive pulmonary disease, bronchiectasis, sarcoidosis, or prior infections). Antifungal medicines are therefore the mainstay of treatment.
However, surgery may be considered in a small and carefully selected group of patients, most commonly when:
1. Disease is localised to one area of the lung
If the aspergillus infection is confined to a single cavity or one lobe, and the rest of the lungs are relatively healthy, it may be technically possible to remove the affected area.
2. Recurrent or life-threatening haemoptysis (coughing up blood)
Large-volume or repeated bleeding is one of the strongest reasons surgery is considered. In some cases, surgery is viewed as a way to prevent catastrophic bleeding, rather than to eradicate infection.
3. A simple aspergilloma
Patients with a simple aspergilloma (a single fungal ball in a cavity, minimal surrounding disease, and preserved lung function) are the group most likely to benefit.
4. Failure or intolerance of antifungal therapy
If antifungal drugs cannot be taken long term due to side effects, drug resistance, or lack of response—and the disease remains localised—surgery may be discussed.
Why surgery is often not recommended
Although surgery can sound appealing, CPA surgery is high-risk and not suitable for most patients.
1. CPA is often widespread
Many patients have a disease affecting both lungs or multiple lobes. Removing one area does not treat the remaining infection.
2. Underlying lung reserve is limited
CPA commonly occurs in people with reduced lung function. Removing lung tissue can lead to:
-
Long-term breathlessness
-
Oxygen dependence
-
Reduced quality of life
Even if the operation itself is technically successful.
3. Surgery carries significant risks
Compared with many other lung operations, CPA surgery has higher complication rates, including:
-
Prolonged air leaks
-
Serious infections
-
Bleeding
-
Bronchopleural fistula (abnormal airway–pleural connection)
-
Need for prolonged hospitalisation or intensive care
4. Surgery does not address the underlying vulnerability
CPA reflects an ongoing susceptibility of the lung environment. Removing one fungal focus does not remove the underlying reason aspergillus was able to grow in the first place.
What is the “success rate” of surgery?
Success depends heavily on patient selection and surgical expertise.
In specialist centres:
-
Operative mortality (risk of death around the time of surgery):
Typically reported between 1–5%, but higher in complex diseases. -
Major complication rates:
Often 15–40%, depending on disease extent and lung health. -
Symptom improvement:
Many patients selected for surgery experience reduced haemoptysis and improved local control of disease.
These figures are why surgery is only offered after careful multidisciplinary discussion, usually involving respiratory physicians, infectious disease specialists, thoracic surgeons, and radiologists.
Is surgery a “cure” for CPA?
This is one of the most misunderstood points.
Short answer: sometimes, but often not in the long term
-
In a simple aspergilloma, surgery can be genuinely curative if:
-
The disease is completely removed
-
There is no other active CPA elsewhere
-
The patient’s lungs remain stable
-
-
In chronic cavitary or fibrosing CPA, surgery is rarely a true cure. Instead, it may:
-
Control bleeding
-
Remove a particularly problematic area
-
Reduce fungal burden
-
Even after apparently successful surgery, some patients still require:
-
Long-term antifungal therapy
-
Ongoing monitoring with scans and blood tests
Recurrence of aspergillus infection elsewhere in the lungs can occur months or years later.
Why are many patients managed medically instead
For most people with CPA, long-term antifungal therapy offers:
-
Disease stabilisation
-
Symptom control
-
Lower risk than surgery
While antifungals do not usually “cure” CPA either, they can:
-
Slow or halt progression
-
Reduce inflammation and symptoms
-
Improve quality of life
This is why surgery is best seen as a highly selective tool, not a standard treatment.
How decisions about surgery are made
If surgery is discussed, your team will usually consider:
-
Extent and pattern of CPA on imaging
-
Lung function tests
-
General fitness and other medical conditions
-
History of haemoptysis
-
Response and tolerance to antifungal treatment
-
Your own priorities and acceptable trade-offs
Importantly, being told surgery is not advised does not mean your care is being limited—it usually reflects a judgement that risks outweigh benefits in your specific case.
Key messages for patients
-
Surgery for CPA is uncommon and highly selective
-
It is most useful in localised disease or severe bleeding
-
Complication rates are significant
-
A guaranteed or permanent “cure” is not typical, except in carefully chosen cases
-
Long-term medical management remains the safest and most effective option for most patients
If surgery has been mentioned—or ruled out—in your case, it is reasonable to ask your team:
-
What specific problem would surgery aim to solve for me?
-
What risks apply to my lungs and overall health?
-
Would antifungal treatment still be needed afterwards?
These discussions are an important part of shared decision-making in CPA care.
Latest News posts
News archive